NZ578053A - Methods of use for cyclopamine analogs - Google Patents

Methods of use for cyclopamine analogs

Info

Publication number
NZ578053A
NZ578053A NZ578053A NZ57805307A NZ578053A NZ 578053 A NZ578053 A NZ 578053A NZ 578053 A NZ578053 A NZ 578053A NZ 57805307 A NZ57805307 A NZ 57805307A NZ 578053 A NZ578053 A NZ 578053A
Authority
NZ
New Zealand
Prior art keywords
cancer
carcinoma
cell carcinoma
hyperproliferative
methods
Prior art date
Application number
NZ578053A
Other languages
English (en)
Inventor
Martin Tremblay
William Matsui
Alfredo C Castro
Michael J Grogan
Karen J Mcgovern
Original Assignee
Infinity Discovery Inc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc, Univ Johns Hopkins filed Critical Infinity Discovery Inc
Publication of NZ578053A publication Critical patent/NZ578053A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J69/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one atom and expansion of only one ring by one atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NZ578053A 2006-12-28 2007-12-27 Methods of use for cyclopamine analogs NZ578053A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87801806P 2006-12-28 2006-12-28
US94159607P 2007-06-01 2007-06-01
PCT/US2007/088995 WO2008083252A2 (en) 2006-12-28 2007-12-27 Methods of use for cyclopamine analogs

Publications (1)

Publication Number Publication Date
NZ578053A true NZ578053A (en) 2012-11-30

Family

ID=39589207

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ578053A NZ578053A (en) 2006-12-28 2007-12-27 Methods of use for cyclopamine analogs
NZ577916A NZ577916A (en) 2006-12-28 2007-12-27 Cyclopamine analogs

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ577916A NZ577916A (en) 2006-12-28 2007-12-27 Cyclopamine analogs

Country Status (25)

Country Link
US (18) US8017648B2 (Direct)
EP (4) EP2368551B1 (Direct)
JP (2) JP5412292B2 (Direct)
KR (2) KR101489394B1 (Direct)
CN (2) CN101631463B (Direct)
AR (1) AR081107A1 (Direct)
AU (2) AU2007339782B2 (Direct)
BR (2) BRPI0720972B8 (Direct)
CA (2) CA2674302C (Direct)
CL (1) CL2007003854A1 (Direct)
DK (1) DK2096917T3 (Direct)
ES (2) ES2612746T3 (Direct)
IL (1) IL199554B (Direct)
JO (1) JO2947B1 (Direct)
MX (3) MX342683B (Direct)
NO (3) NO347310B1 (Direct)
NZ (2) NZ578053A (Direct)
PE (1) PE20090042A1 (Direct)
PL (1) PL2096917T3 (Direct)
PT (1) PT2096917E (Direct)
RU (2) RU2492859C2 (Direct)
SG (2) SG177929A1 (Direct)
TW (1) TWI433674B (Direct)
WO (2) WO2008083248A2 (Direct)
ZA (2) ZA200904445B (Direct)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5204486B2 (ja) 2004-08-27 2013-06-05 インフィニティ ファーマスーティカルズ、インク． シクロパミンアナログ及びその使用方法
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
NZ579356A (en) 2007-03-07 2012-04-27 Infinity Pharmaceuticals Inc Cyclopamine lactam analogs and methods of use thereof
AU2008223355B2 (en) * 2007-03-07 2014-03-20 Infinity Discovery, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
EP2224807B1 (en) * 2007-12-27 2016-11-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US20100222287A1 (en) * 2007-12-27 2010-09-02 Mcgovern Karen J Therapeutic Cancer Treatments
BRPI0821779A2 (pt) * 2007-12-27 2019-09-24 Infinity Pharmaceuticals Inc tratamento terapêutico de câncer
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009099625A2 (en) * 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
WO2010080817A2 (en) * 2009-01-06 2010-07-15 Utah State University Carbohydrate-cyclopamine conjugates as anticancer agents
US20120020876A1 (en) * 2009-01-23 2012-01-26 Kenneth Paul Olive Hedgehog pathway inhibitors
JP6141015B2 (ja) * 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
US20110065645A1 (en) * 2009-09-10 2011-03-17 The Regents Of The University Of California Compositions and Methods for Modulating Neuron Degeneration and Neuron Guidance
CA2779424A1 (en) * 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor
AU2010321773A1 (en) * 2009-11-20 2012-06-14 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
WO2011088404A1 (en) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
CN103002738A (zh) 2010-05-21 2013-03-27 英特利凯恩有限责任公司 用于激酶调节的化学化合物、组合物和方法
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TWI565709B (zh) 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 雜環化合物及其用途
SG11201400310WA (en) 2011-08-29 2014-06-27 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
CA2752008A1 (en) * 2011-09-13 2013-03-13 Universite De Montreal Combination therapy using ribavirin as elf4e inhibitor
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
LT2782584T (lt) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
EP2822558B1 (en) 2012-03-06 2020-02-19 The Board of Trustees of the University of Illionis Procaspase 3 activation by combination therapy
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
HUE033583T2 (hu) 2012-06-21 2017-12-28 Eisai R&D Man Co Ltd Új indánszulfamid származékok
MX386085B (es) 2012-11-01 2025-03-18 Infinity Pharmaceuticals Inc Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa
CA2893133A1 (en) 2012-11-29 2014-06-05 Strasspharma Llc Methods of modulating follicle stimulating hormone activity
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN105793255B (zh) 2013-10-04 2018-11-16 无限药品股份有限公司 杂环化合物及其用途
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9610262B2 (en) 2013-12-19 2017-04-04 Eisai R&D Management Co., Ltd. Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN105232562B (zh) * 2014-07-07 2019-06-28 中国科学院上海巴斯德研究所 一种人呼吸道合胞病毒的抑制剂和抗病毒药物设计靶点
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US20170231968A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
CN105622708B (zh) 2016-02-14 2017-10-10 山东大学 治疗呼吸道合胞病毒感染的化合物及其制备方法与用途
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
SI3432916T1 (sl) 2016-09-13 2020-01-31 Allergan, Inc. Stabilizirani ne-protein klostridijski toksin sestavki
EP3710433A4 (en) 2017-11-17 2022-01-12 The Board of Trustees of the University of Illinois CANCER THERAPY BY REMOVAL OF DOUBLE MEK SIGNALING
CN113329749B (zh) 2018-10-05 2025-02-11 伊利诺伊大学董事会 用于治疗葡萄膜黑色素瘤的联合疗法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN113461771B (zh) * 2020-03-31 2022-09-30 南方科技大学 钠钾atp酶抑制剂的制备方法
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6333341A (ja) 1986-07-28 1988-02-13 Seitetsu Kagaku Co Ltd 配糖体の処理方法
US4843071A (en) 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
JP2851054B2 (ja) 1989-03-15 1999-01-27 サントリー株式会社 ベンズオキセピン誘導体
US5169780A (en) 1989-06-22 1992-12-08 Celgene Corporation Enantiomeric enrichment and stereoselective synthesis of chiral amines
FR2656310B1 (fr) 1989-12-22 1992-05-07 Roussel Uclaf Nouveaux produits sterouides comportant en position 10, un radical thioethyle substitue, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
CA2157594A1 (en) 1993-03-10 1994-09-15 Leah L. Frye Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
IT1265001B1 (it) 1993-12-16 1996-10-17 Zambon Spa Composizione farmaceutica per uso topico contenente acido (s)-2-(4- isobutilfenil) propionico
EP0741783B1 (en) 1993-12-30 2009-03-18 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins
US6281332B1 (en) 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
EP0897300A4 (en) 1995-10-10 2000-07-05 Marilyn Strube TREATMENT OF PRURITUS WITH VITAMIN D AND ITS ANALOGS
US6887820B1 (en) 1995-12-06 2005-05-03 Japan Science And Technology Corporation Method for producing optically active compounds
EP0916637B1 (en) 1995-12-06 2005-04-20 Japan Science and Technology Agency Process for preparating optically active compounds
GB9706321D0 (en) 1997-03-26 1997-05-14 Zeneca Ltd Catalytic hydrogenation
US7709454B2 (en) 1997-06-20 2010-05-04 New York University Methods and compositions for inhibiting tumorigenesis
US7741298B2 (en) 1997-06-20 2010-06-22 New York University Method and compositions for inhibiting tumorigenesis
US6238876B1 (en) 1997-06-20 2001-05-29 New York University Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
US6867216B1 (en) 1998-04-09 2005-03-15 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signal pathways, compositions and uses related thereto
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
CA2339330A1 (en) 1998-08-13 2000-02-24 University Of Southern California Methods to increase blood flow to ischemic tissue
GB9821067D0 (en) 1998-09-29 1998-11-18 Zeneca Ltd Transfer hydrogenation process
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
FR2796938B1 (fr) 1999-07-29 2004-04-02 Ppg Sipsy Nouveaux derives chiraux n-substitues de la norephedrine, leur preparation et leur utilisation pour la synthese de composes fonctionnalises optiquement actifs par transfert d'hydrogene
US20070021493A1 (en) 1999-09-16 2007-01-25 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2001019800A2 (en) 1999-09-16 2001-03-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6993456B2 (en) 1999-09-30 2006-01-31 Rockwell Automation Technologies, Inc. Mechanical-electrical template based method and apparatus
JP5420128B2 (ja) 1999-10-13 2014-02-19 ジョンズ ホプキンス ユニバーシティ スクール オブ メディシン ヘッジホッグ経路の調節物質、並びにそれに関する組成物及び利用法
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP1227805B2 (en) 1999-10-14 2011-02-23 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6893637B1 (en) 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
IL133809A0 (en) 1999-12-30 2001-04-30 Yeda Res & Dev Steroidal alkaloids and pharmaceutical compositions comprising them
KR20010077591A (ko) 2000-02-03 2001-08-20 복성해 아라니콜라 프로테오리티쿠스에서 분리한 신규 금속성단백질 분해효소 및 그의 유전자
US6613798B1 (en) 2000-03-30 2003-09-02 Curis, Inc. Small organic molecule regulators of cell proliferation
CA2404413C (en) 2000-03-30 2015-10-20 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2001090077A1 (en) 2000-05-19 2001-11-29 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
AU9684401A (en) 2000-10-13 2002-04-22 Curis Inc Hedgehog antagonists, methods and uses related thereto
US7708998B2 (en) 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
GB0029356D0 (en) 2000-12-01 2001-01-17 Avecia Ltd Transfer hydrogenation
US6456928B1 (en) 2000-12-29 2002-09-24 Honeywell International Inc. Prognostics monitor for systems that are subject to failure
DE20221841U1 (de) 2001-03-16 2008-05-21 Alza Corp., Mountain View Transdermal-Pflaster zum Verabreichen von Fentanyl
WO2002080952A2 (en) 2001-04-09 2002-10-17 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
AUPR602401A0 (en) 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
EP1411938B1 (en) 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
EP1561464A3 (en) 2001-07-02 2007-04-25 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
RU2308948C2 (ru) * 2001-07-02 2007-10-27 ТАШ Шинан Применение циклопамина для лечения базально-клеточной эпителиомы (карциномы) и других опухолей
NZ530580A (en) 2001-07-27 2007-02-23 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
JP2003192919A (ja) * 2001-10-17 2003-07-09 Asahi Denka Kogyo Kk 難燃性合成樹脂組成物
US7112690B2 (en) 2001-11-09 2006-09-26 National Research Council Of Canada Volatile noble metal organometallic complexes
US7105637B2 (en) 2002-02-15 2006-09-12 William Marsh Rice University Dehydro-estriol (8-DHE3) and dehydro-pregnanetriol (7-DHPT), methods of their synthesis
AU2003209475A1 (en) 2002-03-07 2003-09-16 Vectura Limited Fast melt multiparticulate formulations for oral delivery
JP2005529876A (ja) 2002-04-22 2005-10-06 ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン Ｈｅｄｇｅｈｏｇシグナル伝達経路の調節因子、それに関連する組成物および使用
GB0210234D0 (en) 2002-05-03 2002-06-12 Novartis Ag Process for the manufacture of organic compounds
JPWO2004000863A1 (ja) 2002-06-20 2005-10-20 日本水産株式会社 プロドラッグ、その医薬としての使用、およびその製法
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
GB0221539D0 (en) 2002-09-17 2002-10-23 Medical Res Council Methods of treatment
GB0230217D0 (en) 2002-12-27 2003-02-05 Biotica Tech Ltd Borrelidin-producing polyketide synthase and its uses
FR2850022B1 (fr) 2003-01-22 2006-09-08 Centre Nat Rech Scient Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
JP4750697B2 (ja) 2003-06-25 2011-08-17 オタワ ヘルス リサーチ インスティテュート 幹細胞の成長及び分化を調節する方法及び組成物
WO2005013800A2 (en) 2003-07-15 2005-02-17 The Johns Hopkins University Elevated hedgehog pathway activity in digestive system tumors, and methods of treating digestive system tumors having elevated hedgehog pathway activity
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
US20080095761A1 (en) 2003-10-01 2008-04-24 The Johns Hopkins University Hedgehog Signaling in Prostate Regeneration Neoplasia and Metastasis
US20050136449A1 (en) 2003-10-01 2005-06-23 Invitrogen Corporation Compositions and methods for synthesizing, purifying, and detecting biomolecules
US20070231828A1 (en) 2003-10-01 2007-10-04 Johns Hopkins University Methods of predicting behavior of cancers
WO2005042700A2 (en) 2003-10-20 2005-05-12 The Johns Hopkins University Use of hedgehog pathway inhibitors in small-cell lung cancer
US20070219250A1 (en) 2003-11-28 2007-09-20 Romi Singh Pharmaceutical Compositions of Nateglinide
EP1745041B1 (en) 2004-04-30 2012-06-20 Genentech, Inc. Quinoxaline inhibitors of the hedgehog signalling pathway
JP5204486B2 (ja) 2004-08-27 2013-06-05 インフィニティ ファーマスーティカルズ、インク． シクロパミンアナログ及びその使用方法
KR20210090744A (ko) 2004-09-02 2021-07-20 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
JP2008514726A (ja) 2004-09-30 2008-05-08 ザ ユニヴァーシティー オヴ シカゴ ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法
CN101083996A (zh) 2004-10-28 2007-12-05 Irm责任有限公司 作为hedgehog途径调节剂的化合物和组合物
US20090208579A1 (en) 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060252073A1 (en) 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
US8668905B2 (en) 2005-05-12 2014-03-11 University Of South Florida P53 vaccines for the treatment of cancers
CA2619889C (en) 2005-08-22 2020-05-05 The Johns Hopkins University Use of itraconazole and salts thereof for treating cancer
JP4712524B2 (ja) 2005-10-28 2011-06-29 富士通コンポーネント株式会社 入力デバイス及び電子機器
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
WO2007056135A1 (en) 2005-11-04 2007-05-18 Merck & Co., Inc. Method of treating cancers with saha and pemetrexed
WO2007054623A2 (en) 2005-11-11 2007-05-18 Licentia Oy Mammalian hedgehog signaling inhiabitors
JP5225857B2 (ja) 2005-11-14 2013-07-03 ジェネンテック，インコーポレイティド ヘッジホッグシグナル伝達のビスアミド阻害剤
WO2007076294A2 (en) 2005-12-15 2007-07-05 Wei Chen Method of screening the activity of the smoothened receptor to identify theraputic modulation agents or diagnose disease
CA2635718A1 (en) 2005-12-27 2007-08-09 Genentech, Inc. Methods of using hedgehog kinase antagonists to inhibit hedgehog signaling and to treat hedgehog mediated disorders
EP1818411A1 (en) 2006-02-13 2007-08-15 Lonza AG Process for the preparation of optically active chiral amines
EP1998785A4 (en) 2006-02-21 2009-06-17 Univ Michigan TREATMENT OF CANCER BY AN ANTAGONIST OF THE HEDGEHOG SIGNALING PATH
WO2007123511A2 (en) 2006-03-24 2007-11-01 Infinity Pharmaceuticals, Inc. Dosing regimens for the treatment of cancer
CA2648196A1 (en) 2006-04-14 2007-10-25 Novartis Ag Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
DE102006031358A1 (de) * 2006-07-05 2008-01-17 Schott Ag Verfahren zur Gehäusung optischer oder optoelektronischer Bauteile, sowie verfahrensgemäß herstellbares optisches oder optoelektronisches Gehäuseelement
US20100048944A1 (en) 2006-07-19 2010-02-25 Farhad Parhami Interactions of hedgehog and liver x receptor signaling pathways
PE20080948A1 (es) 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
US20090305338A1 (en) 2006-09-29 2009-12-10 Anneli Ritala-Nurmi Plant cell lines established from the medicinal plant veratrum californicum
JP2010505877A (ja) 2006-10-05 2010-02-25 ザ・ジョンズ・ホプキンス・ユニバーシティー スマートな高分子ナノ粒子を用いた低水溶性薬物用の水分散性経口、非経口および局所的製剤
KR101563010B1 (ko) 2006-10-31 2015-10-26 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 평활화 폴리펩티드 및 사용 방법
US20080103116A1 (en) 2006-11-01 2008-05-01 Jennings-Spring Barbara L Method of treatment and compositions of D-chiro inositol and phosphates thereof
WO2008057497A2 (en) 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2008063166A1 (en) 2006-11-20 2008-05-29 Thomson Licensing Method for eliminating redundant connections
AU2006350960B2 (en) 2006-11-20 2013-09-12 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US20100099116A1 (en) 2007-01-12 2010-04-22 Infinity Discovery, Inc. Methods for Analysis of Hedgehog Pathway Inhibitors
FI123481B (fi) 2007-02-05 2013-05-31 Upm Kymmene Corp Menetelmä painopaperin valmistamiseksi ja seoskoostumus
AU2008223355B2 (en) 2007-03-07 2014-03-20 Infinity Discovery, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
NZ579356A (en) 2007-03-07 2012-04-27 Infinity Pharmaceuticals Inc Cyclopamine lactam analogs and methods of use thereof
MX2009009786A (es) 2007-03-14 2009-09-24 Exelixis Inc Inhibidores de la via de hedgehog.
NZ579402A (en) 2007-03-15 2012-03-30 Novartis Ag Organic compounds for diagnosis and treatment of pathologies relating to the Hedgehog pathway
US9095589B2 (en) 2007-04-05 2015-08-04 Johns Hopkins University Chirally pure isomers of itraconazole for use as angiogenesis inhibitors
AR066063A1 (es) 2007-04-18 2009-07-22 Merck & Co Inc Derivados de triazol que son antagonistas de smo
US20090054517A1 (en) 2007-04-20 2009-02-26 Lubahn Dennis B Phytoestrogens As Regulators Of Hedgehog Signaling And Methods Of Their Use In Cancer Treatment
WO2009009625A2 (en) 2007-07-09 2009-01-15 Eastern Virginia Medical School Substituted nucleoside derivatives with antiviral and antimicrobial properties
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US7867492B2 (en) 2007-10-12 2011-01-11 The John Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies
BRPI0820856A2 (pt) 2007-12-13 2019-05-14 Siena Bhiotech.S.P.A. anatagonista da série de reação de hedgehog e aplicações terapêuticas dos mesmos
US20100297118A1 (en) 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
US20100222287A1 (en) 2007-12-27 2010-09-02 Mcgovern Karen J Therapeutic Cancer Treatments
BRPI0821779A2 (pt) 2007-12-27 2019-09-24 Infinity Pharmaceuticals Inc tratamento terapêutico de câncer
EP2224807B1 (en) 2007-12-27 2016-11-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
WO2009099625A2 (en) 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
US20090246841A1 (en) 2008-03-26 2009-10-01 Jamieson Andrew C Methods and compositions for production of acetaldehyde
US20110217294A1 (en) 2008-04-11 2011-09-08 Daniel Fults Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
CL2009001479A1 (es) 2008-07-02 2010-01-04 Infinity Pharmaceuticals Inc Metodo para aislar un alcaloide del veratrum desglicosilado que comprende proporcionar un material de planta veratrum, poner en contacto con una solucion acuosa y extraer el material de la planta veratrum con un solvente para proporcionar un extracto que comprende dicho alcaloide.
CA2636807A1 (en) 2008-07-04 2010-01-04 Steven Splinter Methods for obtaining cyclopamine
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
PL2342198T3 (pl) 2008-09-17 2013-08-30 Sun Pharma Global Fze Difosforan N-[6-(cis-2,6-dimetylomorfolin-4-ylo)pirydyn-3-ylo]-2-metylo-4’-(trifluorometoksy)[1,1’-bifenylo]-3-karboksyamidu
AU2009294875C1 (en) 2008-09-22 2015-05-14 Aileron Therapeutics, Inc. Methods for preparing purified polypeptide compositions
US20100081637A1 (en) 2008-10-01 2010-04-01 Innovia Skincare Corp. Eczema treatment with vitamin D and analogs thereof method, composition and cream
US20120020876A1 (en) 2009-01-23 2012-01-26 Kenneth Paul Olive Hedgehog pathway inhibitors
AR077490A1 (es) 2009-07-21 2011-08-31 Novartis Ag Composiciones farmaceuticas topicas para el tratamiento de una condicion hiperproliferativa de la piel
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
CA2779424A1 (en) * 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor
AU2010321773A1 (en) 2009-11-20 2012-06-14 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
WO2011088404A1 (en) 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
GB201010954D0 (en) 2010-06-29 2010-08-11 Edko Pazarlama Tanitim Ticaret Compositions
WO2012006584A2 (en) 2010-07-08 2012-01-12 Infinity Pharmaceuticals, Inc. Therapeutic regimens for hedgehog-associated cancers
US20120010230A1 (en) 2010-07-08 2012-01-12 Macdougall John R Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CN102085176A (zh) 2010-12-31 2011-06-08 江苏中丹制药有限公司 一种纳米级伊曲康唑外用制剂、其制备方法及其用途
US8865765B2 (en) 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
US9072660B2 (en) 2011-09-09 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Topical itraconazole formulations and uses thereof
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
RU2015128265A (ru) 2012-12-14 2017-01-25 Треви Терапьютикс, Инк. Способы лечения зуда
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
CA2943100C (en) 2014-03-24 2017-04-04 Hao Wu Quinoline derivatives as smo inhibitors
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus

Also Published As

Publication number Publication date
EP2443926A3 (en) 2012-05-09
EP2368551A8 (en) 2011-11-30
ES2488466T3 (es) 2014-08-27
AU2007339782B2 (en) 2014-05-22
US8785635B2 (en) 2014-07-22
EP2101580B1 (en) 2016-10-12
EP2368551B1 (en) 2013-09-18
US20120077834A1 (en) 2012-03-29
JP5412292B2 (ja) 2014-02-12
US20200121658A1 (en) 2020-04-23
CN101677551B (zh) 2015-01-07
NO343748B1 (no) 2019-05-27
US11602527B2 (en) 2023-03-14
DK2096917T3 (da) 2014-09-15
KR20090119755A (ko) 2009-11-19
US20100286180A1 (en) 2010-11-11
RU2009129000A (ru) 2011-02-10
NZ577916A (en) 2012-11-30
US20130108583A1 (en) 2013-05-02
JP2010514797A (ja) 2010-05-06
US20140107142A1 (en) 2014-04-17
CA2673995C (en) 2016-06-07
EP2096917A2 (en) 2009-09-09
EP2101580A4 (en) 2011-01-05
AU2007339782A1 (en) 2008-07-10
US8669365B2 (en) 2014-03-11
KR20090109545A (ko) 2009-10-20
CA2673995A1 (en) 2008-07-10
US20090216022A1 (en) 2009-08-27
WO2008083248A2 (en) 2008-07-10
RU2492859C2 (ru) 2013-09-20
RU2009128997A (ru) 2011-02-10
US10821102B2 (en) 2020-11-03
US20210275508A1 (en) 2021-09-09
NO344315B1 (no) 2019-11-04
ZA200904445B (en) 2010-12-29
US20170022212A1 (en) 2017-01-26
BRPI0720972B1 (pt) 2020-12-29
US20180338962A1 (en) 2018-11-29
US20080293754A1 (en) 2008-11-27
US20110230509A1 (en) 2011-09-22
US10045970B2 (en) 2018-08-14
US9669011B2 (en) 2017-06-06
MX2009007077A (es) 2009-10-07
US20090012109A1 (en) 2009-01-08
SG177929A1 (en) 2012-02-28
SG177930A1 (en) 2012-02-28
US20130108582A1 (en) 2013-05-02
US7812164B2 (en) 2010-10-12
US8227509B2 (en) 2012-07-24
AU2007339786A1 (en) 2008-07-10
CN101631463A (zh) 2010-01-20
EP2443926A2 (en) 2012-04-25
EP2096917A4 (en) 2011-01-05
US9145422B2 (en) 2015-09-29
JO2947B1 (en) 2016-03-15
WO2008083248A3 (en) 2008-10-16
NO20092710L (no) 2009-09-21
US11007181B2 (en) 2021-05-18
ZA200904446B (en) 2010-12-29
US10314827B2 (en) 2019-06-11
CA2674302C (en) 2017-01-24
CA2674302A1 (en) 2008-07-10
PT2096917E (pt) 2014-08-01
CL2007003854A1 (es) 2008-05-30
WO2008083252A3 (en) 2008-10-30
US20200022962A1 (en) 2020-01-23
WO2008083252A2 (en) 2008-07-10
EP2368551A3 (en) 2011-12-21
US20160158208A1 (en) 2016-06-09
US9951083B2 (en) 2018-04-24
EP2368551A2 (en) 2011-09-28
IL199554B (en) 2018-11-29
US20140371253A1 (en) 2014-12-18
HK1158989A1 (en) 2012-07-27
TWI433674B (zh) 2014-04-11
US20170360763A1 (en) 2017-12-21
US9492435B2 (en) 2016-11-15
MX342683B (es) 2016-10-07
ES2612746T3 (es) 2017-05-18
KR101482693B1 (ko) 2015-01-14
NO20190059A1 (no) 2009-09-21
TW200848034A (en) 2008-12-16
US20190000816A1 (en) 2019-01-03
AU2007339786B2 (en) 2014-05-01
EP2101580A2 (en) 2009-09-23
US8017648B2 (en) 2011-09-13
BRPI0720993B8 (pt) 2021-05-25
US8895576B2 (en) 2014-11-25
US10406139B2 (en) 2019-09-10
RU2486194C2 (ru) 2013-06-27
BRPI0720972A2 (pt) 2016-03-15
NO20092711L (no) 2009-09-21
KR101489394B1 (ko) 2015-02-03
PL2096917T3 (pl) 2015-01-30
PE20090042A1 (es) 2009-04-04
MX2009007075A (es) 2009-12-14
EP2096917B1 (en) 2014-05-07
BRPI0720993A2 (pt) 2017-10-24
NO347310B1 (no) 2023-09-11
BRPI0720972B8 (pt) 2021-05-25
JP5542448B2 (ja) 2014-07-09
JP2010514796A (ja) 2010-05-06
BRPI0720993B1 (pt) 2020-10-13
CN101677551A (zh) 2010-03-24
AR081107A1 (es) 2012-06-27
CN101631463B (zh) 2014-04-02

Similar Documents

Publication Publication Date Title
NZ578053A (en) Methods of use for cyclopamine analogs
CN102036962B (zh) 血管生成抑制剂和紫杉烷的组合使用
CN101848895B (zh) 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
JP2016536283A5 (Direct)
NZ624922A (en) Orally administered corticosteroid compositions
WO2007084450A3 (en) Cannibinoid receptor modulators
EP2769976A1 (en) Hydroxamic acid compound containing quinolyl and preparation method thereof, and pharmaceutical composition containing this compound and use thereof
MX2011002783A (es) Rapalogos, composiciones farmaceuticas, metodos de preparacion y usos de los mismos.
PH12014501925A1 (en) Nitrogen-containing aromatic heterocyclic compound
JP2009544634A5 (Direct)
Sridhar et al. Design, synthesis, biological evaluation and molecular modelling studies of novel diaryl substituted pyrazolyl thiazolidinediones as potent pancreatic lipase inhibitors
WO2008063202A3 (en) Heterobicyclic thiophene compounds for the treatment of cancer
NZ598758A (en) N-4 (-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
WO2009035673A8 (en) Compositions and methods for treating macular degeneration
WO2008024980A3 (en) Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives
TW200724541A (en) Imidazoquinolines as lipid kinase inhibitors
WO2010039762A3 (en) Pharmaceutical compositions comprising boronic acid compounds
WO2010018458A3 (en) Phenol derivatives as hif-alpha modulators
IL202614A0 (en) Intravaginal drug delivery devices for the delivery of macromolecules and water soluble drugs
WO2008073956A3 (en) Cyclic sulfonamide derivatives and methods of their use
HK1197191A1 (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
WO2012031603A3 (en) Airway administration of angiogenesis inhibitors
WO2010022196A3 (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
WO2009097570A3 (en) Intralymphatic chemotherapy drug carriers
Yao et al. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines

Legal Events

Date Code Title Description
S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: THE INVENTORS (72) HAVE BEEN CORRECTED

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 DEC 2014 BY FB RICE

Effective date: 20130516

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2015 BY COMPUTER PACKAGES INC

Effective date: 20141202

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2016 BY COMPUTER PACKAGES INC

Effective date: 20151201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2017 BY COMPUTER PACKAGES INC

Effective date: 20161201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2018 BY COMPUTER PACKAGES INC

Effective date: 20171201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2019 BY COMPUTER PACKAGES INC

Effective date: 20181201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2020 BY COMPUTER PACKAGES INC

Effective date: 20191203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2021 BY COMPUTER PACKAGES INC

Effective date: 20201201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2022 BY COMPUTER PACKAGES INC

Effective date: 20220603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2023 BY COMPUTER PACKAGES INC

Effective date: 20230609

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2024 BY COMPUTER PACKAGES INC

Effective date: 20231130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2025 BY COMPUTER PACKAGES INC

Effective date: 20241130